刺五加提取物 | 137038-13-2

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物 - 木脂素苷
• 中文名称: 刺五加提取物
• 中文别名: 刺五加甙；刺五加甙E1；无梗五加苷B；五加甙B+E
• 英文名称: (+)-syringaresinol O-β-D-glucopyranoside
• 英文别名: (2S,3R,4S,5S,6R)-2-[4-[(3S,3aR,6S,6aR)-3-(4-hydroxy-3,5-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-2,6-dimethoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol；(−)-syringaresinol 4-O-β-D-glucopyranoside；syringaresinol 4′-O-β-D-glucopyranoside；syringaresinol-4′-O-β-D-glucopyranoside；(+)-syringaresinol 4'-O-β-D-glucopyranoside；(+)-syringaresinol 4-O-β-D-glucopyranoside
• CAS: 137038-13-2；7374-79-0
• 化学式: C₂₈H₃₆O₁₃
• 分子量: 580.586
• InChiKey: WEKCEGQSIIQPAQ-IRBNZIFYSA-N

物化性质

• 沸点：
  778.5±60.0 °C(Predicted)
• 密度：
  1.399±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  41
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  175
• 氢给体数：
  5
• 氢受体数：
  13

安全信息

• WGK Germany：
  3

制备方法与用途

生物活性

Episyringaresinol 4'-O-β-D-glncopyranoside (化合物22) 是从鼠尾草（Alhagi sparsifolia Shap）中分离出的一种天然的潜在神经炎症抑制剂。

体外研究

Episyringaresinol 4'-O-β-D-glncopyranoside 在脂多糖（LPS）诱导的N9小胶质细胞中以剂量不依赖的方式显著抑制了NO的产生，其半数有效浓度（IC50）为91.50 μM。

反应信息

• 作为反应物：
  描述：

  刺五加提取物 在 β-glucosidase 作用下， 反应 48.0h， 以35 mg的产率得到(+)-丁香树脂酚
  参考文献：
  名称：

  Studies on the constituents of Cistanchis Herba. V. Isolation and structures of two new phenylpropanoid glycosides, cistanosides E and F.

  摘要：

  从列当科肉苁蓉 (C. A. MEY.) G. BECK (C. A. MEY.) G. BECK (C. A. MEY.) G. BECK (C. A. MEY.) G. BECK (C. A. MEY.) G. BECK (C. A. MEY.) G. BECK (C. A. MEY.) G. BECK (C. A. MEY.) G. BECK (C. A. MEY.) G. BECK (列当科) 的全草中分离得到两种新的苯丙素苷，命名为肉苁蓉苷 E (III) 和 F (IV)。 I) 和 (+)-丁香树脂醇 O-β-D-吡喃葡萄糖苷 (II)。 III和IV的结构确定为2-(4-羟基-3-甲氧基苯基)乙基O-α-L-吡喃鼠李糖基-(1→3)-O-β-D-吡喃葡萄糖苷和α-L-吡喃鼠李糖基( 1→3)-O-(4-O-咖啡酰基)-D-吡喃葡萄糖，分别基于化学和光谱数据。

  DOI：

  10.1248/cpb.33.1452
• 作为产物：
  描述：

  反式芥子醇 在 吡啶 、 氢氧化钾 、 air 、 sodium methylate 、 copper(II) sulfate 作用下， 以 甲醇 、 水 、 丙酮 为溶剂， 反应 49.5h， 生成 刺五加提取物
  参考文献：
  名称：

  Synthesis of biologically active tetrahydro-furofuranlignan-(syringin, pinoresinol)- mono- and bis-glucosides

  摘要：

  The naturally occurring tetrahydrofurofuran-lignan-(syringaresinol, pinoresinol)-mono- and bis-glucosides were synthesized and their structures thereby confirmed.

  DOI：

  10.1016/s0031-9422(00)98258-x

文献信息

• The constituents of Eucommia ulmoides OLIV. II. Isolation and structures of three new lignan glycosides.
  作者：TAKESHI DEYAMA、TAKAKO IKAWA、SANSEI NISHIBE

  DOI：10.1248/cpb.33.3651

  日期：——

  Three new lignan glycosides were isolated from the bark of Eucommia ulmoides OLIV. (Eucommiaceae). Their structures were established as (-)-olivil 4', 4"-di-O-β-D-glucopyranoside (1), (+)-1-hydroxypinoresinol 4', 4"-di-O-β-D-glucopyranoside (2) and (+)-medioresinol 4'-O-β-D-glucopyranoside (named eucommin A) (3), based on chemical evidence and spectroscopic studies. A known lignan glycoside, (+)-syringaresinol O-β-D-glucopyranoside (4) was also isolated.

  从杜仲（Eucommia ulmoides OLIV.(杜仲科）树皮中分离出三种新的木质素苷。根据化学证据和光谱研究，它们的结构被确定为(-)-olivil 4'，4"-di-O-β-D-吡喃葡萄糖苷（1）、(+)-1-hydroxypinoresinol 4'，4"-di-O-β-D-吡喃葡萄糖苷（2）和(+)-medioresinol 4'-O-β-D-吡喃葡萄糖苷（命名为杜仲素 A）（3）。此外，还分离出一种已知的木质素苷，(+)-syringaresinol O-β-D-glucopyranoside（4）。
• PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEMENTIA AND IMPROVING COGNITIVE FUNCTION, COMPRISING GLASSWORT EXTRACT
  申请人：Phyto Corporation Inc.

  公开号：EP3461486A1

  公开（公告）日：2019-04-03

  The present invention relates to a pharmaceutical composition comprising an acanthoside B compound as an effective ingredient for preventing or treating dementia or for improving a cognitive function. In the present invention, a desalted glasswort extract, and acanthoside B, which is isolated from the extract and acts as an effective ingredient inhibitory of acetylcholine esterase, were found to have an excellent neuroprotective activity through the inhibition of neuroinflammation and to improve memory retention and remarkably enhance spatial cognitive ability as measured by passive avoidance test and Y-maze test in a scopolamine-induced amnesic animal model. The acanthoside B or glasswort extract of the present invention can be applied to a pharmaceutical composition.

  本发明涉及一种药物组合物，该组合物包含作为预防或治疗痴呆症或改善认知功能的有效成分的刺桐甙B化合物。在本发明中，发现一种脱盐的玻璃草提取物和从提取物中分离出来的作为抑制乙酰胆碱酯酶的有效成分的刺桐甙 B，通过抑制神经炎症具有极好的神经保护活性，并通过东莨菪碱诱导的失忆动物模型中的被动回避试验和 Y 迷宫试验来改善记忆保持能力和显著提高空间认知能力。本发明的刺桐甙 B 或玻璃草提取物可用于药物组合物中。
• Pharmaceutical composition for preventing or treating dementia and improving cognitive function, comprising glasswort extract
  申请人：PHYTO CORPORATION INC.

  公开号：US10822367B2

  公开（公告）日：2020-11-03

  The present invention relates to a pharmaceutical composition comprising an acanthoside B compound as an effective ingredient for preventing or treating dementia or for improving a cognitive function. In the present invention, a desalted glasswort extract, and acanthoside B, which is isolated from the extract and acts as an effective ingredient inhibitory of acetylcholine esterase, were found to have an excellent neuroprotective activity through the inhibition of neuroinflammation and to improve memory retention and remarkably enhance spatial cognitive ability as measured by passive avoidance test and Y-maze test in a scopolamine-induced amnesic animal model. The acanthoside B or glasswort extract of the present invention can be applied to a pharmaceutical composition for preventing or treating dementia, a pharmaceutical composition for improving a cognitive function, or a health functional food or feed for improving memory retention and cognitive function.

  本发明涉及一种药物组合物，该组合物包含作为预防或治疗痴呆症或改善认知功能的有效成分的刺桐甙B化合物。在本发明中，发现一种脱盐的玻璃草提取物和从提取物中分离出来的作为抑制乙酰胆碱酯酶的有效成分的刺桐甙 B，通过抑制神经炎症具有极好的神经保护活性，并通过东莨菪碱诱导的失忆动物模型中的被动回避试验和 Y 迷宫试验来改善记忆保持能力和显著提高空间认知能力。本发明的刺桐甙 B 或玻璃草提取物可用于预防或治疗痴呆症的药物组合物、改善认知功能的药物组合物或改善记忆保持和认知功能的保健功能食品或饲料。
• FOOD OR FEED COMPOSITION FOR IMPROVING COGNITIVE FUNCTION OR MEMORY COMPRISING EXTRACT OF DESALTED SALICORNIA EUROPAEA
  申请人：PHYTO CORPORATION INC.

  公开号：US20210040133A1

  公开（公告）日：2021-02-11

  The present invention relates to a pharmaceutical composition comprising an acanthoside B compound as an effective ingredient for preventing or treating dementia or for improving a cognitive function. In the present invention, a desalted glasswort extract, and acanthoside B, which is isolated from the extract and acts as an effective ingredient inhibitory of acetylcholine esterase, were found to have an excellent neuroprotective activity through the inhibition of neuroinflammation and to improve memory retention and remarkably enhance spatial cognitive ability as measured by passive avoidance test and Y-maze test in a scopolamine-induced amnesic animal model. The acanthoside B or glasswort extract of the present invention can be applied to a pharmaceutical composition for preventing or treating dementia, a pharmaceutical composition for improving a cognitive function, or a health functional food or feed for improving memory retention and cognitive function.